DENVER, Jul 09, 2009 -- Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP), a medical device company focused on infectious disease and dermatology, today announced that it has entered into an exclusive evaluation and option to license agreement with Nobel Biocare, the world leader in innovative restorative and esthetic dental solutions. Under terms of the Agreement, Nobel Biocare will have an exclusive period to evaluate, negotiate commercialization terms and license the Company's Cerashield(TM) antimicrobial technology for certain oral and cranial maxillofacial applications for a period of up to eleven months. This is the third such agreement entered into by Ceragenix for a medical device application of its CeraShield(TM) antimicrobial technology.
Mr. Steven Porter, Chairman and CEO of Ceragenix, said: "We're very pleased to be working with Nobel Biocare to develop these applications. We believe that attracting a company of this magnitude and caliber is another validation statement of the potential of our technology. We are gaining a lot of momentum with our Cerashield(TM) technology and currently have approximately two dozen material transfer agreements in place with companies evaluating the technology. I expect that these material transfer agreements will result in the execution of several additional development agreements before the end of the year."
About Ceragenix
Ceragenix Pharmaceuticals, Inc. is a medical device company focused on infectious disease and dermatology. The Company has two base technology platforms; Ceragenins(TM) for treatment of infectious disease and Barrier Repair for the treatment of dermatological disorders including atopic dermatitis, neonatal skin disorders and others. Ceragenin(TM) compounds are active against a broad range of gram positive and negative bacteria. We have used our Ceragenin(TM) technology to formulate Cerashield(TM) antimicrobial coatings for medical devices. All Ceragenin(TM) and Cerashield(TM) products are currently in the developmental stage. Ceragenix's patented Barrier Repair technology, invented by Dr. Peter Elias, is the platform for the development of EpiCeram(R) which is currently being marketed by Promius Pharmaceuticals (a wholly owned subsidiary of Dr. Reddy's Laboratories) in the United States under an exclusive supply and distribution agreement. For additional information on Ceragenix, please visit www.ceragenix.com.
About Nobel
Nobel Biocare is a medical devices group and the world leader in innovative esthetic dental solutions with its key brands NobelActive(TM), Branemark System(R), NobelReplace(TM), NobelSpeedy(TM), Replace Select (dental implants), NobelProcera(TM)(individualized dental prosthetics), NobelGuide(TM) (complete patient rehabilitation program) and NobelSmile(TM)(patient education and awareness program). Nobel Biocare is a full solution provider for restorative esthetic dentistry, offering a wide range of innovative Crown & Bridge & Implant products, as well as training and education, patient information and clinically documented treatment concepts. Nobel Biocare has over 2,400 employees and recorded revenue of EUR 619.2 million in 2008. The Company is domiciled and headquartered in Zurich, Switzerland. Production takes place at six production sites located in Sweden, the US, Japan and Israel. Nobel Biocare has 37 direct sales organizations. The shares of the parent company Nobel Biocare Holding AG are listed on the SIX Swiss Exchange.
FORWARD-LOOKING STATEMENTS FOR CERAGENIX.
This press release may contain forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, the following: the ability of our partner to successfully develop a product using the Cerashield(TM) technology, the ability to successfully negotiate license terms if a product is successfully developed by our partner, the ability of the Company to raise sufficient capital to finance its operations and planned activities including completing development of its Ceragenin(TM) technology; the ability of the Company to meet its obligations under the supply and distribution agreement with Dr. Reddy's Laboratories including having sufficient working capital to fulfill purchase orders within the timeframes required by the agreement; the ability of the Company to service its outstanding convertible debt obligations; receiving the necessary marketing clearance approvals from the United States Food and Drug Administration (the "FDA"); successful clinical trials of the Company's planned products including the ability to enroll the studies in a timely manner, patient compliance with the study protocol, and a sufficient number of patients completing the studies; the ability of the Company to commercialize its planned products; the ability of the Company to successfully manufacture its products in commercial quantities (through contract manufacturers); market acceptance of the Company's planned products, the Company's ability to successfully develop its licensed compounds, alone or in cooperation with others, into commercial products, the ability of the Company to successfully prosecute and protect its intellectual property, general economic conditions in the United States and elsewhere, and the Company's ability to hire, manage and retain qualified personnel. The aforementioned factors do represent an all inclusive list. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained in this press release. In particular important factors that could cause actual results to differ materially from our forward-looking statements including general economic factors, business strategies, the state of capital markets, regulatory conditions, and other factors not currently known to us, may be significant, now or in the future, and the factors set forth in this press release may affect us to a greater extent than indicated. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth in this press release and in other documents that we file from time to time with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2008, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K to be filed in 2009. Except as required by law, we do not undertake any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.